Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UAE Drug Regulator Orders Recall Of Schwarz Pharma Heart Drug

This article was originally published in PharmAsia News

Executive Summary

The United Arab Emirates ordered a recall of Germany-based Schwarz Pharma's Nitrocine (glyceryl trinitrate) for treating heart and blood-pressure problems on grounds it may contain impurities.

You may also be interested in...



CMS Building Rx Price Negotiating Staff Internally; Contracting With Outside Groups ‘Not On Radar’

CMS head Brooks-LaSure says agency is making progress in staffing the drug pricing control programs established by the Inflation Reduction Act. Medicare Center deputy director Cheri Rice will be its acting director under just-unveiled management structure.

Health And Wellness Weekly Trademarks Review: 6 December

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Dietary Ingredient Studies For Health Benefits Could Be Fenced In By US FDA IND Proposal

Proposed rule introduces two exemptions agency would allow from needing IND clearance for clinical investigations to evaluate food, supplements or cosmetics. Both begin with basic requirement of trial not intended to support drug development plan or labeling change that would make a food, dietary ingredient or cosmetic an unlawfully marketed drug.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC082422

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel